Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
SUMMARY
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) pipeline Target constitutes close to 35 molecules. Out of which approximately 32 molecules are developed by companies and remaining by the universities/institutes. The latest report Fibroblast Growth Factor Receptor 4 - Drugs In Development, 2022, outlays comprehensive information on the Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Fibroblast growth factor receptor 4 is a protein encoded by the FGFR4 gene. It plays a role in the regulation of cell proliferation, differentiation, and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. It is required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. It phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 5, 6, 3, 8 and 4 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively.
Report covers products from therapy areas Oncology, Gastrointestinal, Metabolic Disorders, Musculoskeletal Disorders, Central Nervous System, Infectious Disease and Undisclosed which include indications Hepatocellular Carcinoma, Solid Tumor, Bile Duct Cancer (Cholangiocarcinoma), Gastric Cancer, Breast Cancer, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Adenocarcinoma Of The Gastroesophageal Junction, Glioblastoma Multiforme (GBM), Lung Adenocarcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Prostate Cancer, Thyroid Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Achondroplasia, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Bladder Cancer, Gastrointestinal Stromal Tumor (GIST), Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Liver Cancer, Muscle Invasive Bladder Cancer (MIBC), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Ovarian Cancer, Rhabdomyosarcoma, Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, Type 2 Diabetes, Anaplastic Thyroid Cancer, Bladder Carcinoma, Childhood Rhabdomyosarcoma, Colorectal Cancer, Constipation, Diarrhea, Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing Sarcoma, Extrahepatic Bile Duct Cancer, Fallopian Tube Cancer, Gallbladder Cancer, Gastrointestinal Tract Cancer, High-Grade Glioma, Human Papillomavirus Infections, Hypopharyngeal Cancer, Kidney Cancer (Renal Cell Cancer), Laryngeal Cancer, Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Liver Cirrhosis, Liver Fibrosis, Low-Grade Glioma, Lymphoma, Malignant Pleural Mesothelioma, Melanoma, Merkel Cell Carcinoma, Metastatic Bile Duct Cancer, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Neuroendocrine Carcinoma, Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Obesity, Oral Cavity (Mouth) Cancer, Oral Mucositis, Oropharyngeal Cancer, Osteosarcoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Paranasal Sinus And Nasal Cavity Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Peritoneal Cancer, Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Primary Sclerosing Cholangitis, Primitive Neuroectodermal Tumor (PNET), Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcomas, Spinal Cord Injury, Squamous Cell Carcinoma, Thymic Carcinoma, Triple-Negative Breast Cancer (TNBC), Unspecified, Ureter Cancer and Urethral Cancer.
Furthermore, this report also reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) pipeline Target constitutes close to 35 molecules. Out of which approximately 32 molecules are developed by companies and remaining by the universities/institutes. The latest report Fibroblast Growth Factor Receptor 4 - Drugs In Development, 2022, outlays comprehensive information on the Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Fibroblast growth factor receptor 4 is a protein encoded by the FGFR4 gene. It plays a role in the regulation of cell proliferation, differentiation, and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. It is required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. It phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 5, 6, 3, 8 and 4 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively.
Report covers products from therapy areas Oncology, Gastrointestinal, Metabolic Disorders, Musculoskeletal Disorders, Central Nervous System, Infectious Disease and Undisclosed which include indications Hepatocellular Carcinoma, Solid Tumor, Bile Duct Cancer (Cholangiocarcinoma), Gastric Cancer, Breast Cancer, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Adenocarcinoma Of The Gastroesophageal Junction, Glioblastoma Multiforme (GBM), Lung Adenocarcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Prostate Cancer, Thyroid Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Achondroplasia, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Bladder Cancer, Gastrointestinal Stromal Tumor (GIST), Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Liver Cancer, Muscle Invasive Bladder Cancer (MIBC), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Ovarian Cancer, Rhabdomyosarcoma, Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, Type 2 Diabetes, Anaplastic Thyroid Cancer, Bladder Carcinoma, Childhood Rhabdomyosarcoma, Colorectal Cancer, Constipation, Diarrhea, Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing Sarcoma, Extrahepatic Bile Duct Cancer, Fallopian Tube Cancer, Gallbladder Cancer, Gastrointestinal Tract Cancer, High-Grade Glioma, Human Papillomavirus Infections, Hypopharyngeal Cancer, Kidney Cancer (Renal Cell Cancer), Laryngeal Cancer, Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Liver Cirrhosis, Liver Fibrosis, Low-Grade Glioma, Lymphoma, Malignant Pleural Mesothelioma, Melanoma, Merkel Cell Carcinoma, Metastatic Bile Duct Cancer, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Neuroendocrine Carcinoma, Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Obesity, Oral Cavity (Mouth) Cancer, Oral Mucositis, Oropharyngeal Cancer, Osteosarcoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Paranasal Sinus And Nasal Cavity Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Peritoneal Cancer, Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Primary Sclerosing Cholangitis, Primitive Neuroectodermal Tumor (PNET), Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcomas, Spinal Cord Injury, Squamous Cell Carcinoma, Thymic Carcinoma, Triple-Negative Breast Cancer (TNBC), Unspecified, Ureter Cancer and Urethral Cancer.
Furthermore, this report also reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
- The report reviews Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Overview
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Abbisko Therapeutics Co Ltd
Applied Pharmaceutical Science Inc
Astellas Pharma Inc
Bayer AG
Betta Pharmaceuticals Co Ltd
BioArdis LLC
Blueprint Medicines Corp
BridgeBio Pharma Inc
BridGene Biosciences Inc
Bristol-Myers Squibb Co
Eddingpharm Inc
Eisai Co Ltd
Eli Lilly and Co
EUSOL Biotech Co Ltd
Everest Medicines Ltd
Genosco Inc
H3 Biomedicine Inc
Heilongjiang ZBD Pharmaceutical Co Ltd
ImmunoForge Co Ltd
InnoCare Pharma Ltd
Jacobio Pharmaceuticals Group Co Ltd
Johnson & Johnson
Merck & Co Inc
NGM Biopharmaceuticals Inc
Shouyao Holding Co Ltd
Tyra Biosciences Inc
Vichem Chemie Research Ltd
Zhejiang Hisun Pharmaceutical Co Ltd
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Drug Profiles
ABSK-011 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ABSK-012 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ABSK-121 - Drug Profile
Product Description
Mechanism Of Action
History of Events
aldafermin - Drug Profile
Product Description
Mechanism Of Action
History of Events
ASP-5878 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BIO-1262 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BPI-43487 - Drug Profile
Product Description
Mechanism Of Action
derazantinib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
EDP-317 - Drug Profile
Product Description
Mechanism Of Action
History of Events
erdafitinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
ES-135 - Drug Profile
Product Description
Mechanism Of Action
History of Events
FGFR2/3/4 Inhibitor - Drug Profile
Product Description
Mechanism Of Action
fisogatinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
Fusion Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
gunagratinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
H-3B6527 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HS-236 - Drug Profile
Product Description
Mechanism Of Action
HZB-1006 - Drug Profile
Product Description
Mechanism Of Action
ICP-105 - Drug Profile
Product Description
Mechanism Of Action
History of Events
infigratinib phosphate - Drug Profile
Product Description
Mechanism Of Action
History of Events
JAB-6343 - Drug Profile
Product Description
Mechanism Of Action
KF-1604 - Drug Profile
Product Description
Mechanism Of Action
History of Events
lenvatinib mesylate - Drug Profile
Product Description
Mechanism Of Action
History of Events
LY-2874455 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Recombinant Protein to Agonize FGFRs for Oral Mucositis - Drug Profile
Product Description
Mechanism Of Action
roblitinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
rogaratinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit FGFR4 for Hepatocellular Carcinoma - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit FGFR4 for Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Antagonize FGFR4 for Hepatocellular Carcinoma - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit FGFR4 for Childhood Rhabdomyosarcoma, Hepatocellular Carcinoma, and Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit FGFR4 for Hepatocellular Carcinoma - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit FGFR4 for Hepatocellular Carcinoma - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit Pan FGFR for Oncology - Drug Profile
Product Description
Mechanism Of Action
SY-4798 - Drug Profile
Product Description
Mechanism Of Action
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Dormant Products
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Discontinued Products
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Mar 07, 2022: Taiwan approves Eisai’s Lenvima combo for endometrial carcinoma
Mar 03, 2022: Helsinn Group and BridgeBio Pharma announce update to strategic collaboration to develop, manufacture and commercialize Infigratinib in oncology indications in the U.S.
Feb 08, 2022: Abbisko Therapeutics completes dosing of the first patient in the phase II clinical trial for ABSK011 in combination with an Anti-PD-L1 antibody
Jan 31, 2022: LENVIMA (lenvatinib) in combination with KEYTRUDA (pembrolizumab) approved in Taiwan for the first-line treatment of patients with advanced renal cell carcinoma
Jan 26, 2022: Progression-free survival and overall survival significantly longer with lenvatinib plus pembrolizumab than with chemotherapy in advanced endometrial cancer
Jan 24, 2022: Basilea reports updated interim results for iCCA patients with FGFR2 mutations and amplifications from phase 2 study FIDES-01 at ASCO GI Cancers Symposium
Jan 20, 2022: Results from pivotal phase 3 study 309/KEYNOTE-775 trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in advanced endometrial carcinoma published in the New England Journal of Medicine
Jan 17, 2022: Eisai to present abstracts on lenvatinib at 2022 ASCO Gastrointestinal Cancers Symposium
Jan 14, 2022: Eisai to present research at the 2022 ASCO Gastrointestinal Cancers Symposium in multiple tumor types from its robust oncology portfolio
Jan 05, 2022: Knight Therapeutics announces approval of Lenvima in Colombia
Dec 24, 2021: LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) approved in Japan for patients with Unresectable, advanced or recurrent endometrial carcinoma that progressed after cancer chemotherapy
Dec 21, 2021: Helsinn Group announces European Medicines Agency’s (EMA) acceptance for review of the marketing authorization application (MAA) for infigratinib for patients with cholangiocarcinoma with fibroblast growth factor receptor 2 fusions or rearrangements
Dec 21, 2021: LianBio announces infigratinib approved under special named patient program for the treatment of cholangiocarcinoma in the pilot zone of Hainan province in China
Oct 19, 2021: Abbisko Therapeutics announces the IND approval by NMPA for phase II clinical trial of ABSK011
Oct 18, 2021: Eisai and Merck & Co Kenilworth, N.J., U.S.A. receive positive EU CHMP opinions for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in two different types of cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Overview
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Abbisko Therapeutics Co Ltd
Applied Pharmaceutical Science Inc
Astellas Pharma Inc
Bayer AG
Betta Pharmaceuticals Co Ltd
BioArdis LLC
Blueprint Medicines Corp
BridgeBio Pharma Inc
BridGene Biosciences Inc
Bristol-Myers Squibb Co
Eddingpharm Inc
Eisai Co Ltd
Eli Lilly and Co
EUSOL Biotech Co Ltd
Everest Medicines Ltd
Genosco Inc
H3 Biomedicine Inc
Heilongjiang ZBD Pharmaceutical Co Ltd
ImmunoForge Co Ltd
InnoCare Pharma Ltd
Jacobio Pharmaceuticals Group Co Ltd
Johnson & Johnson
Merck & Co Inc
NGM Biopharmaceuticals Inc
Shouyao Holding Co Ltd
Tyra Biosciences Inc
Vichem Chemie Research Ltd
Zhejiang Hisun Pharmaceutical Co Ltd
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Drug Profiles
ABSK-011 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ABSK-012 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ABSK-121 - Drug Profile
Product Description
Mechanism Of Action
History of Events
aldafermin - Drug Profile
Product Description
Mechanism Of Action
History of Events
ASP-5878 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BIO-1262 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BPI-43487 - Drug Profile
Product Description
Mechanism Of Action
derazantinib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
EDP-317 - Drug Profile
Product Description
Mechanism Of Action
History of Events
erdafitinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
ES-135 - Drug Profile
Product Description
Mechanism Of Action
History of Events
FGFR2/3/4 Inhibitor - Drug Profile
Product Description
Mechanism Of Action
fisogatinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
Fusion Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
gunagratinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
H-3B6527 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HS-236 - Drug Profile
Product Description
Mechanism Of Action
HZB-1006 - Drug Profile
Product Description
Mechanism Of Action
ICP-105 - Drug Profile
Product Description
Mechanism Of Action
History of Events
infigratinib phosphate - Drug Profile
Product Description
Mechanism Of Action
History of Events
JAB-6343 - Drug Profile
Product Description
Mechanism Of Action
KF-1604 - Drug Profile
Product Description
Mechanism Of Action
History of Events
lenvatinib mesylate - Drug Profile
Product Description
Mechanism Of Action
History of Events
LY-2874455 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Recombinant Protein to Agonize FGFRs for Oral Mucositis - Drug Profile
Product Description
Mechanism Of Action
roblitinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
rogaratinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit FGFR4 for Hepatocellular Carcinoma - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit FGFR4 for Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Antagonize FGFR4 for Hepatocellular Carcinoma - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit FGFR4 for Childhood Rhabdomyosarcoma, Hepatocellular Carcinoma, and Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit FGFR4 for Hepatocellular Carcinoma - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit FGFR4 for Hepatocellular Carcinoma - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit Pan FGFR for Oncology - Drug Profile
Product Description
Mechanism Of Action
SY-4798 - Drug Profile
Product Description
Mechanism Of Action
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Dormant Products
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Discontinued Products
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Mar 07, 2022: Taiwan approves Eisai’s Lenvima combo for endometrial carcinoma
Mar 03, 2022: Helsinn Group and BridgeBio Pharma announce update to strategic collaboration to develop, manufacture and commercialize Infigratinib in oncology indications in the U.S.
Feb 08, 2022: Abbisko Therapeutics completes dosing of the first patient in the phase II clinical trial for ABSK011 in combination with an Anti-PD-L1 antibody
Jan 31, 2022: LENVIMA (lenvatinib) in combination with KEYTRUDA (pembrolizumab) approved in Taiwan for the first-line treatment of patients with advanced renal cell carcinoma
Jan 26, 2022: Progression-free survival and overall survival significantly longer with lenvatinib plus pembrolizumab than with chemotherapy in advanced endometrial cancer
Jan 24, 2022: Basilea reports updated interim results for iCCA patients with FGFR2 mutations and amplifications from phase 2 study FIDES-01 at ASCO GI Cancers Symposium
Jan 20, 2022: Results from pivotal phase 3 study 309/KEYNOTE-775 trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in advanced endometrial carcinoma published in the New England Journal of Medicine
Jan 17, 2022: Eisai to present abstracts on lenvatinib at 2022 ASCO Gastrointestinal Cancers Symposium
Jan 14, 2022: Eisai to present research at the 2022 ASCO Gastrointestinal Cancers Symposium in multiple tumor types from its robust oncology portfolio
Jan 05, 2022: Knight Therapeutics announces approval of Lenvima in Colombia
Dec 24, 2021: LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) approved in Japan for patients with Unresectable, advanced or recurrent endometrial carcinoma that progressed after cancer chemotherapy
Dec 21, 2021: Helsinn Group announces European Medicines Agency’s (EMA) acceptance for review of the marketing authorization application (MAA) for infigratinib for patients with cholangiocarcinoma with fibroblast growth factor receptor 2 fusions or rearrangements
Dec 21, 2021: LianBio announces infigratinib approved under special named patient program for the treatment of cholangiocarcinoma in the pilot zone of Hainan province in China
Oct 19, 2021: Abbisko Therapeutics announces the IND approval by NMPA for phase II clinical trial of ABSK011
Oct 18, 2021: Eisai and Merck & Co Kenilworth, N.J., U.S.A. receive positive EU CHMP opinions for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in two different types of cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Indications, 2022 (Contd..2)
Number of Products under Development by Indications, 2022 (Contd..3)
Number of Products under Development by Indications, 2022 (Contd..4)
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Companies, 2022 (Contd..4)
Products under Development by Companies, 2022 (Contd..5)
Products under Development by Companies, 2022 (Contd..6)
Products under Development by Companies, 2022 (Contd..7)
Products under Development by Companies, 2022 (Contd..8)
Products under Development by Companies, 2022 (Contd..9)
Products under Development by Companies, 2022 (Contd..10)
Products under Development by Companies, 2022 (Contd..11)
Products under Development by Companies, 2022 (Contd..12)
Products under Development by Companies, 2022 (Contd..13)
Products under Development by Companies, 2022 (Contd..14)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Abbisko Therapeutics Co Ltd, 2022
Pipeline by Applied Pharmaceutical Science Inc, 2022
Pipeline by Astellas Pharma Inc, 2022
Pipeline by Bayer AG, 2022
Pipeline by Betta Pharmaceuticals Co Ltd, 2022
Pipeline by BioArdis LLC, 2022
Pipeline by Blueprint Medicines Corp, 2022
Pipeline by BridgeBio Pharma Inc, 2022
Pipeline by BridGene Biosciences Inc, 2022
Pipeline by Bristol-Myers Squibb Co, 2022
Pipeline by Eddingpharm Inc, 2022
Pipeline by Eisai Co Ltd, 2022
Pipeline by Eli Lilly and Co, 2022
Pipeline by EUSOL Biotech Co Ltd, 2022
Pipeline by Everest Medicines Ltd, 2022
Pipeline by Genosco Inc, 2022
Pipeline by H3 Biomedicine Inc, 2022
Pipeline by Heilongjiang ZBD Pharmaceutical Co Ltd, 2022
Pipeline by ImmunoForge Co Ltd, 2022
Pipeline by InnoCare Pharma Ltd, 2022
Pipeline by Jacobio Pharmaceuticals Group Co Ltd, 2022
Pipeline by Johnson & Johnson, 2022
Pipeline by Merck & Co Inc, 2022
Pipeline by NGM Biopharmaceuticals Inc, 2022
Pipeline by Shouyao Holding Co Ltd, 2022
Pipeline by Tyra Biosciences Inc, 2022
Pipeline by Vichem Chemie Research Ltd, 2022
Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Discontinued Products, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Indications, 2022 (Contd..2)
Number of Products under Development by Indications, 2022 (Contd..3)
Number of Products under Development by Indications, 2022 (Contd..4)
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Companies, 2022 (Contd..4)
Products under Development by Companies, 2022 (Contd..5)
Products under Development by Companies, 2022 (Contd..6)
Products under Development by Companies, 2022 (Contd..7)
Products under Development by Companies, 2022 (Contd..8)
Products under Development by Companies, 2022 (Contd..9)
Products under Development by Companies, 2022 (Contd..10)
Products under Development by Companies, 2022 (Contd..11)
Products under Development by Companies, 2022 (Contd..12)
Products under Development by Companies, 2022 (Contd..13)
Products under Development by Companies, 2022 (Contd..14)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Abbisko Therapeutics Co Ltd, 2022
Pipeline by Applied Pharmaceutical Science Inc, 2022
Pipeline by Astellas Pharma Inc, 2022
Pipeline by Bayer AG, 2022
Pipeline by Betta Pharmaceuticals Co Ltd, 2022
Pipeline by BioArdis LLC, 2022
Pipeline by Blueprint Medicines Corp, 2022
Pipeline by BridgeBio Pharma Inc, 2022
Pipeline by BridGene Biosciences Inc, 2022
Pipeline by Bristol-Myers Squibb Co, 2022
Pipeline by Eddingpharm Inc, 2022
Pipeline by Eisai Co Ltd, 2022
Pipeline by Eli Lilly and Co, 2022
Pipeline by EUSOL Biotech Co Ltd, 2022
Pipeline by Everest Medicines Ltd, 2022
Pipeline by Genosco Inc, 2022
Pipeline by H3 Biomedicine Inc, 2022
Pipeline by Heilongjiang ZBD Pharmaceutical Co Ltd, 2022
Pipeline by ImmunoForge Co Ltd, 2022
Pipeline by InnoCare Pharma Ltd, 2022
Pipeline by Jacobio Pharmaceuticals Group Co Ltd, 2022
Pipeline by Johnson & Johnson, 2022
Pipeline by Merck & Co Inc, 2022
Pipeline by NGM Biopharmaceuticals Inc, 2022
Pipeline by Shouyao Holding Co Ltd, 2022
Pipeline by Tyra Biosciences Inc, 2022
Pipeline by Vichem Chemie Research Ltd, 2022
Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Discontinued Products, 2022
LIST OF FIGURES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
